Kyverna Therapeutics

Kyverna Therapeutics (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company headquartered in Emeryville, California, developing engineered T cell therapies for patients suffering from autoimmune diseases. Kyverna adapts CD19 CAR T-cell therapy — originally developed for B cell cancers — to deeply deplete the B cells that drive autoimmunity, with the goal of durable, drug-free remission. Its lead candidate, mivocabtagene autoleucel (miv-cel, KYV-101), is a fully human CD19 CAR T-cell therapy in Phase 2 development for stiff person syndrome, myasthenia gravis and multiple sclerosis, and in Phase 1/2 development for systemic sclerosis and lupus nephritis in the United States and Germany. The pipeline also includes next-generation autologous and allogeneic CAR T constructs, including KYV-201, built on the company's Ingenui-T rapid manufacturing platform. Kyverna is a biopharmaceutical operating company and publishes no public developer API, SDK, or developer portal; this profile tracks its public web, corporate and investor surface within the API Evangelist network.

Kyverna Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotech Therapeutics, Biotechnology, Cell Therapy, and CAR T.

Kyverna Therapeutics’ developer surface includes engineering blog and 17 more developer resources.

🌐 Visit website 📡 Source on GitHub

11.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiotech TherapeuticsBiotechnologyCell TherapyCAR TAutoimmune DiseaseImmunologyNeurologyRheumatologyClinical TrialsLife SciencesPublic Company

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 11.2/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 2.1 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/kyverna-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Get Started 1

Portal, sign-up, and the first successful call

ClinicalTrials

ClinicalTrials

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

PrivacyPolicyEU

PrivacyPolicyEU

Company 7

The organization behind the API

Website

Website

About

About

Blog

Blog

InvestorRelations

InvestorRelations

Careers

Careers

LinkedIn

Twitter

Twitter

Scroll for all 7

Other 5

Properties that don't map to a standard resource type

Leadership

Pipeline

Technology

KnowledgeCenter

Publications

Source (apis.yml)

aid: kyverna-therapeutics
name: Kyverna Therapeutics
description: 'Kyverna Therapeutics (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company headquartered
  in Emeryville, California, developing engineered T cell therapies for patients suffering from autoimmune diseases. Kyverna
  adapts CD19 CAR T-cell therapy — originally developed for B cell cancers — to deeply deplete the B cells that drive autoimmunity,
  with the goal of durable, drug-free remission. Its lead candidate, mivocabtagene autoleucel (miv-cel, KYV-101), is a fully
  human CD19 CAR T-cell therapy in Phase 2 development for stiff person syndrome, myasthenia gravis and multiple sclerosis,
  and in Phase 1/2 development for systemic sclerosis and lupus nephritis in the United States and Germany. The pipeline also
  includes next-generation autologous and allogeneic CAR T constructs, including KYV-201, built on the company''s Ingenui-T
  rapid manufacturing platform. Kyverna is a biopharmaceutical operating company and publishes no public developer API, SDK,
  or developer portal; this profile tracks its public web, corporate and investor surface within the API Evangelist network.'
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kyverna.wpenginepowered.com/wp-content/uploads/2024/12/KYV3000_Kyverna_Logo_CMYK_Reverse_i1_1-new.png
url: https://raw.githubusercontent.com/api-evangelist/kyverna-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- insight-partners
x-tier: stub
x-tier-reason: no-public-api-surface
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biotech Therapeutics
- Biotechnology
- Cell Therapy
- CAR T
- Autoimmune Disease
- Immunology
- Neurology
- Rheumatology
- Clinical Trials
- Life Sciences
- Public Company
apis: []
common:
- type: DomainSecurity
  url: security/kyverna-therapeutics-domain-security.yml
- type: Website
  url: https://kyvernatx.com/
- type: About
  url: https://kyvernatx.com/inside-kyverna/
- type: Contact
  url: https://kyvernatx.com/contact/
- type: Leadership
  url: https://kyvernatx.com/leadership/
- type: Pipeline
  url: https://kyvernatx.com/platform-pipeline/pipeline/
- type: Technology
  url: https://kyvernatx.com/platform-pipeline/car-t-cell-therapy/
- type: ClinicalTrials
  url: https://kyvernatx.com/platform-pipeline/clinical-trials/
- type: KnowledgeCenter
  url: https://kyvernatx.com/knowledge-center/
- type: Publications
  url: https://kyvernatx.com/knowledge-center/publications/
- type: Blog
  url: https://ir.kyvernatx.com/news-releases
- type: InvestorRelations
  url: https://ir.kyvernatx.com/
- type: Careers
  url: https://kyvernatx.com/careers/
- type: PrivacyPolicy
  url: https://kyvernatx.com/privacy-policy/
- type: PrivacyPolicyEU
  url: https://kyvernatx.com/privacy-policy-eu-uk/
- type: LinkedIn
  url: https://www.linkedin.com/company/kyverna/
- type: Twitter
  url: https://x.com/Kyverna_Tx/
- type: LLMsTxt
  url: llms/kyverna-therapeutics-llms.txt
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence